A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata
Genes · 2023
DOI: 10.3390/genes14030744 ↗Kurz gefasst
Fallbericht in der Zeitschrift Genes, 2023. Verfasst von Yue Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China. Hauptthemen laut MEDLINE: Kidney Neoplasms, Uterine Neoplasms, Leiomyomatosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Clinical Research Plan of SHDC.
Abstract (Originalsprache)
Background
HLRCC syndrome is a hereditary cancer predisposition syndrome caused by heterozygous germline pathogenic variant of the fumarate hydratase (FH) gene and characterized by cutaneous leiomyomas (CL), uterine leiomyomas (UL), and renal cell carcinoma (RCC). Loss of function variant of FH gene inactivates the Kreb’s cycle enzyme activity and predisposes individuals with such variant to the development of HLRCC.
Methods
Next-generation sequencing (NGS) and Sanger confirmation were given to family members accessible. Following that, a functional study in vitro was performed to further confirm the pathogenicity of the variant. FH-Wild type (FH-WT) and FH-mutant (FH-MUT) (E378K) plasmid were constructed and transfected into 293T and uterine leiomyoma cell lines, respectively. Proliferation assessment was executed to show how this mutation affects the growth of uterine leiomyoma. qPCR and Western blotting were performed to investigate the change of transcription and translation of FH with mutation (E378K), and FH enzyme assay activity were tested in 293T cells with mutation and wild-type plasmids.
Results
Here, we presented two families with the same missense variant (c.1132G > A) that has not been reported as a germline mutation in hereditary uterine leiomyomas before and classified as VUS in gene databases. Our in vitro experiments supported the pathogenicity of this missense variant, especially in uterine leiomyomata.
Conclusions
According to the American College of Medical Genetics (ACMG) guideline, the E378K variant was classified as likely pathogenic (with evidence PS4_support, PS3_support, PM2_support, PP1, PP3 and PP4 evidence). Further insights into clinical management in uterine leiomyomata were discussed and should be practiced in gynecological clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
- Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
ORCID-Profile: Yue Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Clinical Research Plan of SHDC
- Shanghai Science and technology committee medical guidance program
- Shanghai “Rising Stars of Medical Talent” Youth Development Program-Outstanding Youth Medical Talents
Zitieren
APA
Shi, Y., Xu, Y., Wang, C., Chen, Y., Ren, X., Kang, Y., & Wang, C. (2023). A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata. Genes. https://doi.org/10.3390/genes14030744
Vancouver
Shi Y, Xu Y, Wang C, Chen Y, Ren X, Kang Y, et al. A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata. Genes. 2023. doi:10.3390/genes14030744
BibTeX
@article{Shi2023,
author = {Shi, Yue and Xu, Yan and Wang, Chao and Chen, Yiqing and Ren, Xiaojun and Kang, Yu and Wang, Chao},
title = {A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14030744}
}
EUVIMED